Flu/ Influenza Vaccines And Vaccination

Influenza vaccines, also known as flu shots or jabs, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza. The World Health Organization (WHO) and  Centers for Disease Control and Prevention (CDC), The European Centre for Disease Prevention and Control recommends yearly vaccination for nearly all people over the age of six months, especially those at high risk.

Immune responses to viral infections involve a complex orchestration between innate signals and adaptive responses of specific T and B cells. Advances in T-Cell Therapies and several antiviral compounds have been developed against influenza virus to interfere with specific events in the replication cycle. Among them, the inhibitors of viral uncoating (amantadine), nucleoside inhibitors (ribavirin), viral transcription and neuraminidase inhibitors (zanamivir and oseltamivir) are reported as examples of traditional virus-based antiviral strategies. Thus, the discovery of novel anti-influenza drugs that target general cell signaling pathways essential for viral replication, irrespective to the specific origin of the virus, would decrease the emergence of drug resistance and increase the effectiveness towards different strains of influenza virus. The genome of an influenza virus particle is encased in a capsid that consists of protein. The influenza A capsid contains the antigenic glycoproteins hemagglutinin (HA) and neuraminidase (NA). For genetic analysis Genome sequencing is used which is the process that determines the order, or sequence, of the nucleotides in each of the genes present in the virus’s genome. There are Next Generation Sequencing and Sanger reaction available methods for genome sequencing. Influenza viruses undergo continual antigenic variation, which requires the annual reformulation of trivalent influenza vaccines, making influenza unique among pathogens for which vaccines have been developed. Reverse genetics techniques are also proving to be important for the development of pandemic influenza vaccines, because the technology provides a means to modify genes to remove virulence determinants found in highly pathogenic avian strains.

  • Vaccine innovation and human health
  • Effectiveness of multivalent vaccines
  • Developing a universal flu vaccine
  • Success and challenges of vaccines on infants, children, pregnant women and elderly patient
  • Various influenza vaccine delivery technologies

Related Conference of Flu/ Influenza Vaccines And Vaccination

October 30-November 1, 2017

3rd Annual Congress on Rare Diseases and Orphan Drugs


(10 Plenary Forums - 1 Event)
San Antonio, Texas, USA
November 06-07, 2017

3rd International Conference on Flu and Emerging Infectious Diseases

Las Vegas, Nevada, USA
December 07-08, 2017

EuroSciCon Conference on STD-AIDS

Rome, Italy
March 1-2, 2018

5th International congress on Infectious Diseases

Berlin, Germany
June 11-12, 2018

4th World Congress on Rare Diseases and Orphan Drugs

Dublin, Ireland
July 23-25, 2018

11th World Congress on Infectious Diseases and Therapy

Melbourne, Australia
August 13-14,2018

Global Experts Meeting on Infectious Diseases

Tokyo,Japan
August 27-28, 2018

9th International Conference on Emerging Infectious Diseases

Zurich, Switzerland
September 17-18, 2018

4th Annual Congress on Infectious Diseases

San Diego, USA
September 27-29, 2018

10thEuro-Global Conference on Infectious Diseases

Rome, Italy

Flu/ Influenza Vaccines And Vaccination Conference Speakers

Recommended Sessions

Related Journals

Are you interested in